Starting Treatment with Agonist Replacement Therapies (START) Study

The CTN collaborated with the Division of Pharmacotherapies & Medical Consequences of Drug Abuse (DPMCDA) on this multi-centered trial to compare the effect of buprenorphine/naloxone (Bup/Nx) and methadone (MET) on liver function. This was a randomized, open-label, multi-center, Phase 4 study in participants entering opioid agonist treatment programs at community centers (methadone centers) throughout the country. The study randomized approximately 1,300 participants at 8 sites across 6 Nodes.

3c522ea199ab47c8d4d3963f9ea7f8bc NCT00315341

Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu

Walter Ling, M.D.

Director

Integrated Substance Abuse Programs

University of California, Los Angeles

11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA, 90025, US

lwalter@ucla.edu

CTN-0027 DSMB-0027

Participating Sites

Bay Area Addiction Research/Treatment , California
Matrix Institute on Addictions, California
Northeast Treatment Centers , Delaware
Connecticut Counseling Centers, Inc. , Connecticut
CODA, Inc. , Oregon
Evergreen Treatment Services , Washington

completed